Send to

Choose Destination
J Biol Chem. 2017 May 5;292(18):7395-7406. doi: 10.1074/jbc.M116.753525. Epub 2017 Mar 16.

Amyloid-β oligomers transiently inhibit AMP-activated kinase and cause metabolic defects in hippocampal neurons.

Author information

From the Institute of Medical Biochemistry Leopoldo de Meis and.
the Institute of Biophysics Carlos Chagas Filho.
the Divisions of Neurology/Epilepsy Program and.
Neurosurgery, Clementino Fraga Filho Hospital, Federal University of Rio De Janeiro, Rio de Janeiro 21941-902, Brazil.
the Department of Neurobiology, Northwestern University, Evanston, Illinois 60208-3520, and.
From the Institute of Medical Biochemistry Leopoldo de Meis and
the Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario K7L 3N6, Canada.


AMP-activated kinase (AMPK) is a key player in energy sensing and metabolic reprogramming under cellular energy restriction. Several studies have linked impaired AMPK function to peripheral metabolic diseases such as diabetes. However, the impact of neurological disorders, such as Alzheimer disease (AD), on AMPK function and downstream effects of altered AMPK activity on neuronal metabolism have been investigated only recently. Here, we report the impact of Aβ oligomers (AβOs), synaptotoxins that accumulate in AD brains, on neuronal AMPK activity. Short-term exposure of cultured rat hippocampal neurons or ex vivo human cortical slices to AβOs transiently decreased intracellular ATP levels and AMPK activity, as evaluated by its phosphorylation at threonine residue 172 (AMPK-Thr(P)172). The AβO-dependent reduction in AMPK-Thr(P)172 levels was mediated by glutamate receptors of the N-methyl-d-aspartate (NMDA) subtype and resulted in removal of glucose transporters (GLUTs) from the surfaces of dendritic processes in hippocampal neurons. Importantly, insulin prevented the AβO-induced inhibition of AMPK. Our results establish a novel toxic impact of AβOs on neuronal metabolism and suggest that AβO-induced, NMDA receptor-mediated AMPK inhibition may play a key role in early brain metabolic defects in AD.


AMP-activated kinase (AMPK); ATP; Alzheimer disease; GLUTs; N-methyl-d-aspartate receptor (NMDA receptor, NMDAR); amyloid-β oligomers; energy metabolism

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center